Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Research ArticleSpecial Issue IUPHAR Compendium of the Pharmacology and Classification of the Nuclear Receptor Superfamily 2006

International Union of Pharmacology. LXVI. Orphan Nuclear Receptors

Gérard Benoit, Austin Cooney, Vincent Giguere, Holly Ingraham, Mitch Lazar, George Muscat, Thomas Perlmann, Jean-Paul Renaud, John Schwabe, Frances Sladek, Ming-Jer Tsai and Vincent Laudet
Pharmacological Reviews December 2006, 58 (4) 798-836; DOI: https://doi.org/10.1124/pr.58.4.10
Gérard Benoit
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Austin Cooney
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Giguere
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Ingraham
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitch Lazar
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Muscat
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Perlmann
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Paul Renaud
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Schwabe
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances Sladek
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Jer Tsai
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Laudet
Structure and Evolution of Nuclear Hormone Receptors, Unité Mixte de Recherche 5161 du Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique 1237, Laboratoire de Biologie Moléculaire de la Cellule, Institut Fédératif de Recherche 128 BioSciences Lyon-Gerland, Ecole Normale Supérieure de Lyon, Lyon, France (G.B., V.L.); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (A.C., M.-J.T.); Molecular Oncology Group, McGill University Health Centre, Montréal, Québec, Canada (V.G.); Department of Physiology, University of California, San Francisco, San Francisco, California (H.I.); Division of Endocrinology, Diabetes, and Metabolism, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.L.); Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia (G.M.); Ludwig Institute for Cancer Research, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden (T.P.); AliX, Illkirch, France (J.-P.R.); Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom (J.S.); and Department of Cell Biology and Neuroscience, University of California, Riverside, California (F.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Half of the members of the nuclear receptors superfamily are so-called “orphan” receptors because the identity of their ligand, if any, is unknown. Because of their important biological roles, the study of orphan receptors has attracted much attention recently and has resulted in rapid advances that have helped in the discovery of novel signaling pathways. In this review we present the main features of orphan receptors, discuss the structure of their ligand-binding domains and their biological functions. The paradoxical existence of a pharmacology of orphan receptors, a rapidly growing and innovative field, is highlighted.

Introduction

The cloning of genes encoding the specific receptors for known hormones such as steroids, thyroid hormones, and vitamin-derived compounds such as retinoids and vitamin D3, as well as functional demonstration of their implication in fundamental biological processes of therapeutic interest, led to an intensive search for related proteins predicted to share similar features (Mangelsdorf et al., 1995; Chambon, 1996). The defining structural and functional features of nuclear receptors are a conserved zinc finger DNA-binding domain (DBD1) and a ligand-binding domain (LBD). The evolutionary combination of these functional domains led to the generation of a diverse family of ligand-activated transcription factors that regulate gene expression in response to ligand binding. The high degree of similarity among the first receptors identified, both at the structural and functional levels, set the stage for the search for other family members, initially by low stringency screening of cDNA libraries and polymerase chain reaction screens with degenerate primers (Giguere et al., 1988; Wang et al., 1989; Becker-Andre et al., 1993) and more recently by genome sequence analysis (Robinson-Rechavi and Laudet, 2003). These efforts led to the successful identification of the vast majority of known nuclear receptors (NRs) without prior knowledge of their ligand and defined the gene family (Blumberg and Evans, 1998). In humans, these proteins, referred to as orphan nuclear receptors, still represent half of the total number of NRs (24 of a total of 48 different genes in human).

The discovery of the orphan NRs has raised several questions concerning their physiological functions and the existence of specific ligand(s) and possibly new endocrine systems and has shifted “endocrinology into reverse” (Kliewer et al., 1999; Shiau et al., 2001). Thus, the search for biological function and ligands for orphan NRs has become the subject of intense investigation. In this introductory review we will briefly present these molecules and their diverse biological functions and discuss how the search for ligands has led to a refinement of our definition of a NR ligand.

What Are Orphan Receptors?

The definition of orphan receptors is a loose and paradoxical one because, by definition, orphan receptors are receptors for which no ligand is known. The term “receptor” itself implies that a physiological ligand should exist, even though there is still no consensus in the field as to whether this will be true for all orphan NRs. Because the absence of proof is not the proof of absence, it is extremely difficult to demonstrate that a given orphan NR truly has no endogenous ligand. Complicating the issue is the fact that once a natural ligand has been discovered for an orphan NR, the receptor is no longer considered to be an orphan, despite the fact that it may retain structural and functional features more similar to the other orphan NRs than to the classic steroid and thyroid hormone receptors. Two prime examples are the RXRs and PPARs, which were discovered as orphan NRs, but which are now clearly considered to be liganded receptors, although the precise identity of their physiological, endogenous ligands is somewhat controversial (Gottlicher et al., 1992; Heyman et al., 1992; Kitareewan et al., 1996; Lemotte et al., 1996; Mata de Urquiza et al., 2000; Willson et al., 2000; Lengqvist et al., 2004). Together with the RXRs and PPARs, the FXRs, LXRs, CAR, and PXR have been classified as a new type of NRs that are considered natural sensors (Janowski et al., 1996; Lehmann et al., 1998; Kawamoto et al., 1999; Makishima et al., 1999; Tzameli et al., 2000; Tzameli and Moore, 2001; Francis et al., 2003). The ligand-binding pocket of these receptors is larger than those of classic receptors (such as RARs, TRs, or steroid receptors), and they bind a large diversity of molecules with lower affinity (typically in the micromolar range) (Benoit et al., 2004). Even though some compounds were found inside the pocket of some orphan receptors such as HNF-4, RORs, or SF-1, they still are firmly part of the orphan receptor group because the regulatory role of the compound is unclear and/or the physiological relevance of the interaction with the receptor has not been clearly established (Dhe-Paganon et al., 2002; Kallen et al., 2004; Li et al., 2005; Stehlin et al., 2001; Wisely et al., 2002). Thus, the composition of the orphan receptor group is likely to continue to shrink in the future.

Following this definition, the orphan receptors form a highly diverse group. In fact, orphan receptors are not linked functionally or evolutionarily. In phylogenetic trees of NRs, they are scattered among the six defined subfamilies (Escriva et al., 2000). In addition, their structures are also highly diverse, not only at the structural level within the LBD as discussed below but also in the other domains (Fig. 1). Indeed, some orphan receptors have only one of the two characteristic domains of the NR superfamily. In vertebrates, DAX-1 and SHP, which contain only an LBD and lack a classic DBD with conserved cysteines as do the other receptors, are examples of such divergent orphan receptors (Zanaria et al., 1994; Burris et al., 1996; Seol et al., 1996). In other species (e.g., Drosophila or nematodes), there are several other examples of receptors containing only the LBD or only the DBD sequence. The size of the other domains is also variable; the A/B region of some orphan receptors is extremely short: 8 amino acids for some isoforms of RORβ and 14 amino acids in TLX, whereas in other cases this domain is quite long (250-280 amino acids for NGFI-B/NR4A group members). Like some liganded receptors, such as the RARs, the HNF-4 group members contain an F domain that modulates their transcriptional activities (Ruse et al., 2002).

The diversity of orphan receptors is also illustrated by various modes of binding to DNA. Although most of them seem to bind to DNA as homodimers on direct repeat elements (HNF-4, COUP-TFs, and TR2/4), some interact with RXRs (NGFI-B and NURR1) (Perlmann and Jansson, 1995), and probably the most singular example of a DNA-binding mechanism is the oligomerization of the orphan GCNF upon binding to a direct repeat AGGTCAAGGTCA (Gu et al., 2005c). This divergent DNA-binding mechanism of GCNF, hexamer formation, is probably a reflection of its being the only member in the distant sub-branch 6 of the superfamily. Importantly, the study of several orphan receptors (Reverbs, RORs, SF-1, NGFI-B, NURR1, NOR1, and ERRs) allowed definition of a new type of interaction with DNA, namely, monomer binding to half-site sequences (Wilson et al., 1993). Even though such an ability has been found in a few cases for liganded receptors (e.g., TRα), the functional relevance of monomeric binding is clear only for orphan receptors. In all cases, binding occurs on a conserved A/GGGTCA binding motif that is preceded by an A/T-rich region in 5′. The sequence of this A/T-rich region is variable from one receptor type to another. SF-1, LRH-1, and ERRs bind to TCAA/GGGTCA elements (called SFRE or ERRE) (Honda et al., 1993; Sladek et al., 1997), whereas NGFI-B/NR4A group members bind to AAA/GGGTCA elements (called NBRE) (Wilson et al., 1991). Lastly, Rev-erbs and RORs bind to a less constrained sequence, the consensus of which is A/TAA/TNTA/GGGTCA and is termed a RevRE or a RORE (Harding and Lazar, 1993; Giguère et al., 1994). In addition, Rev-erbs have been described to bind as homodimers to special DR2 elements, called RevDR2, in which the 5′ element, a RevRE, and the 3′ element, a classic A/GGGTCA, are separated by two bases, most often CT (Harding and Lazar, 1995). In all of these cases of monomeric binding to extended half-site sequences, the interaction between the receptor and DNA is in the A/GGGTCA motif, with a recognition helix at the C-terminal part of the first zinc finger interacting with the major groove of DNA and making specific contacts with the A/GGGTCA motif. A second helix in the second zinc finger stabilizes the interaction with DNA and allows dimerization with partners, when partners are present. In addition, the C-terminal part of the receptor is able to interact specifically with the extended 5′ element. Several detailed functional studies plus structural analyses, including one of the Rev-erb DBD associated with DNA, led to the identification of a region beyond the core DBD (C domain), called the A box, that forms a third α-helix of the DBD and is implicated in the recognition of the 5′ extension of the DNA element (Wilson, 1993; Rastinejad et al., 1995). In fact, it has now been shown that variations of this structural element can be found in liganded receptors, such as TRs or RXRs. This is a nice illustration of the impact that orphan receptors can have on the study and understanding of liganded receptors.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Phylogenetic tree and schematic structure of orphan nuclear receptors present in human, mouse, and rat.

Biological Functions of Orphan Receptors

Given the wide diversity of orphan receptors, it is, of course, very difficult to summarize their biological functions (Giguere, 1999). Two points are nevertheless important to mention and to discuss. 1) All orphan receptors have a very important function that is specific to each one of them. Thus, they are not inert molecules, less important than classic receptors. Indeed, gene targeting in the mouse has revealed important, often essential, roles for orphan NRs in development and adult physiology. 2) Orphan receptors often play an important role in modulating the action of classic liganded receptors.

It is possible to generate a very short summary of the functions played by these molecules and because the function of most of them has been inactivated in the mouse or in other biological models, we have a fairly clear understanding of their role, even if, of course, many questions remain. Many orphan receptors are important players in development and cell differentiation. For example, HNF-4α is critical for early mouse development as well as for the development of the liver in vertebrates and arthropods (Watt et al., 2003). COUPTFs have a conserved fundamental role in nervous system development as illustrated in mouse, zebrafish, and even hydra (Cooney et al., 2001) as well as in organo-genesis of various organs (Park et al., 2003). The three NGFI-B members are also important players in brain development (Perlmann and Wallen-Mackenzie, 2004) and in T-cell biology (He, 2002). ERRα in zebrafish (Bardet et al., 2005) and ERRβ in mouse (Luo et al., 1997) have crucial roles in very early development, for example, during gastrulation. In addition ERRα has been proposed to regulate osteoblastic differentiation at later stages of mouse embryogenesis (Bonnelye et al., 1997). GCNF has been shown to play an important role in early mouse development (Chung et al., 2001). GCNF plays a pivotal role in the silencing of pluripotency gene expression at gastrulation and ES cell differentiation (Fuhrmann et al., 2001; Gu et al., 2005b). DAX-1 is specifically implicated in germ cell differentiation in mouse (Achermann, 2005; Zechel, 2005), whereas the TLX receptor and PNR also play an important role during development, for example, in retina formation (Kobayashi et al., 1999). SF-1 plays a central role in the development of steroidogenic tissues, the adrenals and gonads, whereas its close homolog LRH-1 plays a role in endoderm differentiation and maintenance of pluripotence in early embryos (Pare et al., 2004; Gu et al., 2005a).

In addition, orphan receptors have also an important role in adult physiology in regulating metabolism. This is the case for ERRα, which is important for adipogenesis and energy metabolism (Sladek and Giguere, 2000; Luo et al., 2003), but also for the previously mentioned LRH-1 and SF-1, which are critical players in the regulation of cholesterol metabolism in the liver as well as in steroidogenic tissues (Fayard et al., 2004). HNF-4s, COUP-TFs, Rev-erbs, and RORs also play a role in regulating metabolism (especially in cholesterol and fatty acid metabolism) (Jetten et al., 2001; Jetten, 2004; Laitinen et al., 2005), although their specific functions are not yet well understood.

Finally, an emerging, yet poorly characterized, role for orphan receptors is in the regulation of circadian rhythm, a function probably tightly linked to their role in metabolism (Inoue et al., 2005). Rev-erbs and RORs are prominent members of the circadian pacemaker in peripheral tissues as well as in the master clock organ, the suprachiasmatic nucleus (Alvarez and Sehgal, 2002; Preitner et al., 2002, 2003; Emery and Reppert, 2004; Jetten, 2004; Triqueneaux et al., 2004; Guillaumond et al., 2005). Other orphan receptors, such as ERRα, SHP, or EAR2, are also expressed in a circadian manner, and it is interesting to note that the knockout of EAR2 in the mouse exhibits a circadian phenotype (Horard et al., 2004; Warnecke et al., 2005).

Many experiments have demonstrated that orphan receptors regulate the activity of liganded receptors. This is the case for COUP-TFs, TR2, and TR4 (and also to a lesser extent for HNF-4s), which have been shown to repress the activation mediated by liganded receptors such as RAR, TR, or PPAR (Lee et al., 2002; Park et al., 2003). DAX-1 and in a broader sense SHP are regulators of the activity of other receptors (either orphan or liganded) by direct interaction with these receptors (Zhang and Dufau, 2004; Bavner et al., 2005). These highly unusual members of the NR superfamily can even be described as corepressors because they do not bind DNA and do not dimerize with other NRs through the canonical homo-/heterodimerization interface but rather through the cofactor interface. Another case is the connection that exists between ERRs and estrogen signaling. It has been shown that ERRs and ERs share both structural and functional attributes, such as synthetic ligands, interactions with coactivators, and binding to similar DNA sequences in vitro (Giguere, 2002). Many of these connections were found during the early days of orphan receptor research, when researchers were avidly searching for a functional role of these molecules. Thus, it has to be emphasized that many of these experiments were done in transient transfection assays and that in some cases their biological relevance in vivo still awaits confirmation.

Unorthodox LBD for Unorthodox NRs

Two main strategies were developed to search for orphan receptor ligands. These were based either on the search for the ligand per se by focused or random screening of naturally occurring or synthetic compounds (Chawla et al., 2001) or alternatively through the resolution of the structure of the NR LBD by X-ray crystallography. The successful identification of fatty acids, oxysterols, and bile acids as naturally occurring agonists of the PPARs (Gottlicher et al., 1992), the LXRs (Janowski et al., 1996), and the FXR (Makishima et al., 1999; Parks et al., 1999), respectively, led to the suggestion that all NRs may be ligand-regulated. However, it seems that some orphan NRs were resistant to the traditional screening approaches, especially those displaying some level of constitutive activation (i.e., NGFI-B and NURR1) or repression (i.e., Rev-erbs). More recently, evolutionary studies have suggested and structural studies have shown that there are orphan NRs, in which the LBD can carry out its regulatory functions without the need for a ligand.

In contrast to classic liganded receptors, many orphan receptors show a “constitutive” AF-2-dependent transcriptional activity in different biological systems. How this group of receptors (RORs, ERRs, HNF4s, NURRs, and LRH-1) achieves this constitutive activity is of considerable interest to the understanding the function of these orphan NRs. This question was recently elucidated by analysis of the crystal structure of their LBDs. Interestingly, the answers seem to be just as diverse as the LBD structure is conserved, further indicating that the NR family evolved in multiple directions and took advantage of a single structure, namely the LBD, to achieve different physiological functions. In contrast to the screening approaches, which focused on the ligand only, the characterization of the crystal structure of NR LBDs yielded insights into the capacity of a given NR to be regulated by a ligand and in some cases even led to the direct identification of cocrystallized chemical compounds. In addition, and most importantly, the resolution of these structures has led to a refinement of the definition of what is a ligand of a NR. There are four different possibilities for orphan receptors and their potential ligand: 1) receptors with no ligand-binding pocket at all; 2) receptors with empty ligand-binding pockets; 3) receptors with structural ligands; and 4) receptors regulated by ligands, but the physiological relevance of those remains an open question. There are still many receptors, for which we simply have no clear information. This fifth category is the largest one and contains the COUP-TFs, GCNF, TLX, PNR, TR2/4, and DAX/SHP. We will now briefly examine the four possibilities.

The case of NURR1 is probably the most convincing for a receptor containing no ligand-binding pocket (LBP) (Wang et al., 2003). Because the Drosophila homolog of NURR1 (Baker et al., 2003), called DHR38, has the same features as NURR1, it has been suggested that the two other members of the group are characterized by a comparable structure. This hypothesis was since verified for NGFI-B (Flaig et al., 2005). The NGFI-B/NR4A group members form a branch of nuclear receptor homologs expressed in various cell types. When transfected into mammalian cells, all NR4A family members act as constitutively active transcription factors, and all early attempts to define ligands for them have failed. Interestingly, the crystallographic analysis of the NURR1 and DHR38 LBDs reveals that these proteins lack a ligand-binding pocket. The overall structures are very similar to the canonical LBD fold (Wurtz et al., 1996), but bulky amino acid side chains occupy the space that would normally form the LBP. In the crystal structure of the NURR1 LBD, helix 12 is in the active conformation explaining the known constitutive activity of NR4A receptors. It was also revealed that residues conserved between canonical receptors forming the so-called “charge clamp” region, which is required for coactivator binding, are substituted in the NURR1 LBD. These observations and the fact that the NURR1 LBD does not interact with classic p160 coactivators raise questions about the mechanism by which NURR1 activates transcription. More recently, several studies revealed the existence of an alternative coactivator binding cleft (Codina et al., 2004, 2005; Flaig et al., 2005; Volakakis et al., 2006), but cofactors for NR4A family members that use that cleft have not yet been identified. It is now evident that despite obvious similarity to canonical LBDs, NR4A family members are not receptors and are regulated at the level of their expression or via post-translational modifications triggered by intracellular signaling pathways. The Rev-erbs, which are potent transcriptional repressors, are also good candidates to be orphan receptors with no LBP, because modeling studies have suggested that, as for NURR1, the LBP is filled with amino acid side chains (Renaud et al., 2000). A note of caution is nevertheless required here, because this result is only based on modeling studies, not on the experimental determination of the structure. Interestingly, the Drosophila homolog of Rev-erb, E75, is regulated by a unique mechanism. E75, in fact, contains a heme prosthetic group in the LBP, which by controlling the oxidation state of the heme iron, gases, such as nitric oxide or carbon monoxide, controls the activity of the receptor (Reinking et al., 2005). This exemplifies the unexpected diversity of mechanisms that regulate orphan NR activity.

The second interesting case is represented by orphan receptors that have a constitutive activity but in which an empty LBP has been observed. This is the case for ERRγ, for which the structure of the LBD in complex with the SRC-1 peptide was determined (Greschik et al., 2002). This structure reveals a helix 12 in active conformation and a small, but empty, LBP. Similar results were obtained more recently with the structure of the ERRα LBD in complex with a PGC1 peptide (Kallen et al., 2004). There are known examples of compounds able to block the constitutive activity of ERRγ. Notably, these are widely used synthetic antiestrogens, such as 4-hydroxytamoxifen (Coward et al., 2001). Interestingly, and in contrast to other cases such as RORβ (see below), the activity of ERRγ does decline after LBP is blocked with bulky amino acid side chains. Antiestrogens, however, no longer inactivate such mutants. In summary, ERRγ and possibly ERRα and ERRβ are nuclear receptors that are activated by default, but which are also capable of responding to deactivating ligands (Coward et al., 2001; Tremblay et al., 2001a,b), although the physiological relevance of these ligands has not yet been demonstrated. Mouse LRH-1 is another example of an orphan receptor with a large and empty hydrophobic pocket (Sablin et al., 2003), but because this feature seems to be different for the human LRH-1, it will be further discussed below.

Several receptors contain ligands that are unable to leave the receptor and are in fact part of the structure itself. These “structural ligands” that behave as prosthetic groups are usually fatty acids or fatty acid derivatives. This fact is illustrated by the HNF-4s, which form another distinct group of constitutively active nuclear receptors (Dhe-Paganon et al., 2002; Wisely et al., 2002). Analysis of the structure of the HNF-4γ LBD revealed the presence of fatty acids, which could not be displaced from the LBP without protein denaturation (Wisely et al., 2002a). The helix 12 was in an active conformation, and mutations of the LBP designed to prohibit the binding of fatty acids reduced the constitutive activity of the receptor. Thermal denaturation studies of mutated HNF-4α derivatives, however, indicated reduced stability of variants unable to bind fatty acids. Taken together, these studies suggest that HNF4s evolved to position their AF-2 into active conformation without the involvement of the ligand but instead need the help of lipophilic fatty acids to globally fold the LBD. Therefore, HNF-4s may not be nuclear receptors in the classic sense. However, the activity of HNF-4s is regulated at the transcriptional level and by coexpression of regulatory factors, such as SHP. Two other examples in insects, Drosophila USP (Billas et al., 2001; Clayton et al., 2001) and E75 (as mentioned above), are also cases of receptors bound to prosthetic groups, namely, a phospholipid and a heme, respectively.

Finally, researchers are currently in the process of identifying ligands for some orphan NRs such as RORs, LRH-1 and SF-1, the members of subfamily 5. RORα is constitutively active, and its LBD can efficiently recruit p300 and glucocorticoid receptor interacting protein co-activators, which shifts the AF-2 into the active conformation. A surprising feature of the RORα LBP is that this domain copurifies with a cholesterol molecule inside (Kallen et al., 2002, 2004). Interestingly, cholesterol bound in the LBP can be exchanged with cholesterol sulfate, which, using structural predictions, is expected to be a more potent ligand. In addition, changes in the intracellular level of cholesterol modulate RORα transcriptional activity. These results suggest that RORα could potentially serve as a cellular cholesterol “sensor” (Willson, 2002). Cholesterol fills the RORα LBP either to stabilize helix 12 in an active conformation or to globally assist the folding of the LBD. The latter possibility is compatible with the cholesterol receptor hypothesis for RORα. In summary, RORα differs from canonical nuclear receptors in that it is bound to its ligand constitutively, but reversibly. The LBP of the RORβ nuclear receptor, like its homolog RORα, was originally crystallized together with a fortuitously captured molecule of stearic acid (Stehlin et al., 2001). Additional experiments established that stearate did not fulfill the criteria for a true RORβ ligand. Because mutagenesis studies designed to block the RORβ ligand-binding pocket yielded inactive receptors, the search for a RORβ ligand continued. This resulted in the discovery that the well-known RAR natural agonist all-trans-retinoid acid binds the RORβ LBD with low, but biologically relevant, affinity (Stehlin-Gaon et al., 2003). In addition, all-trans-retinoic acid acts as a partial cell-type specific antagonist for RORβ. Many questions remain concerning the in vivo relevance of these interesting observations, and more work is needed before RORα can be considered a real cholesterol sensor and RORβ a third type of retinoic acid receptor.

An even more striking scenario is represented by LRH-1 and SF-1. The mouse LRH-1 LBD assembles into the active conformation with a large, but empty, LBP (Sablin et al., 2003). The ability of helix 12 of LRH-1 to associate with the LBD core was attributed to an unusual helix 2 structure, which forms a unique fourth outer layer of the LBD and actively contributes to the maintenance of the basal activity of the receptor as demonstrated by site-directed mutagenesis (Sablin et al., 2003). Additional experiments aimed at artificially “filling” the LRH-1 LBP with bulky amino acid side chains resulted in an increase of basal activity of the receptor, suggesting that mouse LRH-1 is still ligand-responsive. Strikingly, the determination of the structure of the human LRH-1 as well as of mouse and human SF-1 shows that these receptors, in contrast to mouse LRH-1, bind phosphatidyl inositol second messengers and that ligand binding is required for maximal activity (Krylova et al., 2005; Li et al., 2005; Wang et al., 2005). In line with these findings, mutations of specific amino acids that are part of the LBP of mouse SF-1 induce a loss of activity. The question, of course, remains whether these “fortuitous” ligands that were discovered because they were captured in the LBP during overexpression in bacteria are natural ligands or are at least indicative of the existence of natural ligands. An important and still unanswered question is whether these ligands can really enter and leave the LBD freely (i.e., act as bona fide signaling molecules) and by doing so regulate its transcriptional activity.

All of these observations illustrate the tremendous diversity that exists for orphan receptors with respect to their relationships with small molecules and allows us to redefine the term “ligand” for nuclear receptors. Historically, since the discovery of the superfamily started with the characterization of steroid receptors (i.e., receptors with nanomolar affinity for very selective ligands that are typically hormones synthesized in specific tissues in the organism), it was thought that most, if not all, NRs should have ligands with similar characteristics. The characterization of “sensors” such as PPARs, LXRs, FXRs, PXR/CAR, and even RXRs has prompted a reevaluation of this definition because the LBDs of these receptors bind a large number of molecules, often derived from food or intermediate metabolism products and present at very high physiological concentrations relative to steroid hormones, with a much lower affinity (typically in the micromolar range). Thus, it became clear that NRs do bind not only hormones or morphogens, such as retinoic acid, but also a much broader set of small molecules. If we consider all orphan receptors, we can see that there is a continuum between small molecules forming prosthetic groups tightly linked to the receptor and exchangeable molecules with signaling activities. The main challenge for future work will be to decipher which of the newly discovered “ligands” of orphan receptors are physiologically relevant molecules with a signaling role (i.e., carrying biological information). For this, the emphasis will have to shift from structural studies that were extremely powerful in revealing the nature of these molecules to in vivo analyses of their biological role.

However, in trying to physiologically link a new ligand to an orphan receptor, an instructive paradigm to look at is the estrogen receptors and the enzyme, aromatase, that produces their ligand. The reproductive roles of the estrogen receptors α and β were succinctly determined by gene targeting (Lubahn et al., 1993; Krege et al., 1998; Dupont et al., 2000). The reproductive phenotype of the aromatase knockout only reinforced its role in producing the signal that regulates the estrogen receptors (Fisher et al., 1998; Honda et al., 1998; Nemoto et al., 2000). Thus, inactivation of an enzyme that produces a putative ligand should phenocopy part or all of a receptor phenotype.

The Paradox: Toward Pharmacology of Orphan Receptors?

To conclude, one cannot help but comment that this wide diversity of mechanisms is very good news for pharmacologists. Examples such as ERRγ clearly show that even if an orphan NR has apparently no ligand and an empty pocket, it can still be a valid pharmaceutical target, potentially bound and regulated by drug molecules. The same is likely to be true for other receptors, such as LRH-1, SF-1, and the RORs, making them promising pharmaceutical targets as well.

Finally, it is also important to note that numerous orphan receptors form heterodimers with RXR (Mangelsdorf and Evans, 1995). This functional property seems to be critical for the true orphans of the NR4A subfamily (NGFI-B and NURR1 but not NOR1) (Perlmann and Jansson, 1995; Zetterstrom et al., 1996), because these heterodimers were shown to be responsive to RXR specific ligands, adding yet another mechanism by which the transcriptional activity of these physiologically essential receptors can be regulated.

Tables 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 summarize the functions, biologic activities, structural properties, and ligands of these receptors.

View this table:
  • View inline
  • View popup
TABLE 1

DAX-1

View this table:
  • View inline
  • View popup
TABLE 2

SHP

View this table:
  • View inline
  • View popup
TABLE 3

Rev-erbα

View this table:
  • View inline
  • View popup
TABLE 4

Rev-erbβ

View this table:
  • View inline
  • View popup
TABLE 5

RORα

View this table:
  • View inline
  • View popup
TABLE 6

RORβ

View this table:
  • View inline
  • View popup
TABLE 7

RORγ

View this table:
  • View inline
  • View popup
TABLE 8

HNFα

View this table:
  • View inline
  • View popup
TABLE 9

HNF-4γ

View this table:
  • View inline
  • View popup
TABLE 10

TR2

View this table:
  • View inline
  • View popup
TABLE 11

TR4

View this table:
  • View inline
  • View popup
TABLE 12

TLX

View this table:
  • View inline
  • View popup
TABLE 13

PNR

View this table:
  • View inline
  • View popup
TABLE 14

COUP-TFI

View this table:
  • View inline
  • View popup
TABLE 15

COUP-TFII

View this table:
  • View inline
  • View popup
TABLE 16

EAR2

View this table:
  • View inline
  • View popup
TABLE 17

ERRα

View this table:
  • View inline
  • View popup
TABLE 18

ERRβ

View this table:
  • View inline
  • View popup
TABLE 19

ERRγ

View this table:
  • View inline
  • View popup
TABLE 20

NGFI-B

View this table:
  • View inline
  • View popup
TABLE 21

NURR1

View this table:
  • View inline
  • View popup
TABLE 22

NOR1

View this table:
  • View inline
  • View popup
TABLE 23

SF-1

View this table:
  • View inline
  • View popup
TABLE 24

LRH-1

View this table:
  • View inline
  • View popup
TABLE 25

GCNF

Footnotes

  • ↵1 Abbreviations: DBD, DNA-binding domain; LBD, ligand-binding domain; NR, nuclear receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; FXR, farnesoid X receptor; LXR, liver X receptor; CAR, constitutive androstane receptor; PXR, pregnane X receptor; RAR, retinoic acid receptor; TR, thyroid hormone receptor; HNF, hepatocyte nuclear factor; ROR, retinoid-related orphan receptor; SF-1, steroidogenic factor 1; DAX-1, dosage-sensitive sex reversal-adrenal hypoplasia congenital critical region on the X chromosome protein 1; SHP, small heterodimer partner; TLX, tailless; NGFI-B, nerve growth factor-induced clone B; COUP-TF, chicken ovalbumin upstream promoter transcription factor; TR2, testicular receptor 2; TR4, testicular receptor 4; NURR1, Nur-related factor 1; GCNF, germ cell nuclear factor; NOR1, neuron-derived orphan receptor 1; ERR, estrogen-related receptor; LRH, liver receptor homolog; DR, direct repeat; PNR, photoreceptor-specific nuclear receptor; EAR, ErbA-related protein; ER, estrogen receptor; AF, activation factor; LBP, ligand-binding pocket.

  • J.-P.R. is President and CEO/CSO of AliX, S.A., a biopharmaceutical company working in the field of orphan nuclear receptors.

  • Article, publication date, and citation information can be found at http://pharmrev.aspetjournals.org.

  • doi:10.1124/pr.58.4.10.

  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Achermann JC (2005) The role of SF1/DAX1 in adrenal and reproductive function. Ann Endocrinol (Paris) 66: 233-239.
    OpenUrlPubMed
  2. ↵
    Alvarez JD and Sehgal A (2002) REV-ving up the clock. Dev Cell 3: 150-152.
    OpenUrlCrossRefPubMed
  3. ↵
    Baker KD, Shewchuk LM, Kozlova T, Makishima M, Hassell A, Wisely B, Caravella JA, Lambert MH, Reinking JL, Krause H, et al. (2003) The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. Cell 113: 731-742.
    OpenUrlCrossRefPubMed
  4. ↵
    Bardet PL, Horard B, Laudet V, and Vanacker JM (2005) The ERRα orphan nuclear receptor controls morphogenetic movements during zebrafish gastrulation. Dev Biol 281: 102-111.
    OpenUrlCrossRefPubMed
  5. ↵
    Bavner A, Sanyal S, Gustafsson JA, and Treuter E (2005) Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrinol Metab 16: 478-488.
    OpenUrlCrossRefPubMed
  6. ↵
    Becker-Andre M, Andre E, and DeLamarter JF (1993) Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Biochem Biophys Res Commun 194: 1371-1379.
    OpenUrlCrossRefPubMed
  7. ↵
    Benoit G, Malewicz M, and Perlmann T (2004) Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell Biol 14: 369-376.
    OpenUrlCrossRefPubMed
  8. ↵
    Billas IM, Moulinier L, Rochel N, and Moras D (2001) Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects. J Biol Chem 276: 7465-7474.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Blumberg B and Evans RM (1998) Orphan nuclear receptors—new ligands and new possibilities. Genes Dev 12: 3149-3155.
    OpenUrlFREE Full Text
  10. ↵
    Bonnelye E, Vanacker JM, Dittmar T, Begue A, Desbiens X, Denhardt DT, Aubin JE, Laudet V, and Fournier B (1997) The ERR-1 orphan receptor is a transcriptional activator expressed during bone development. Mol Endocrinol 11: 905-916.
    OpenUrlCrossRefPubMed
  11. ↵
    Burris TP, Guo W, and McCabe ER (1996) The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Recent Prog Horm Res 51: 241-259; discussion 59-60.
    OpenUrlPubMed
  12. ↵
    Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954.
    OpenUrlAbstract
  13. ↵
    Chawla A, Repa JJ, Evans RM, and Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science (Wash DC) 294: 1866-1870.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Chung AC, Katz D, Pereira FA, Jackson KJ, DeMayo FJ, Cooney AJ, and O'Malley BW (2001) Loss of orphan receptor germ cell nuclear factor function results in ectopic development of the tail bud and a novel posterior truncation. Mol Cell Biol 21: 663-677.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Clayton GM, Peak-Chew SY, Evans RM, and Schwabe JW (2001) The structure of the ultraspiracle ligand-binding domain reveals a nuclear receptor locked in an inactive conformation. Proc Natl Acad Sci USA 98: 1549-1554.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Codina A, Benoit G, Gooch JT, Neuhaus D, Perlmann T, and Schwabe JW (2004) Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting. J Biol Chem 279: 53338-53345.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Codina A, Love JD, Li Y, Lazar MA, Neuhaus D, and Schwabe JW (2005) Structural insights into the interaction and activation of histone deacetylase 3 by nuclear receptor corepressors. Proc Natl Acad Sci USA 102: 6009-6014.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Cooney AJ, Lee CT, Lin SC, Tsai SY, and Tsai MJ (2001) Physiological function of the orphans GCNF and COUP-TF. Trends Endocrinol Metab 12: 247-251.
    OpenUrlCrossRefPubMed
  19. ↵
    Coward P, Lee D, Hull MV, and Lehmann JM (2001) 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ. Proc Natl Acad Sci USA 98: 8880-8884.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Dhe-Paganon S, Duda K, Iwamoto M, Chi YI, and Shoelson SE (2002) Crystal structure of the HNF4α ligand binding domain in complex with endogenous fatty acid ligand. J Biol Chem 277: 37973-37976.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, and Mark M (2000) Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes. Development 127: 4277-4291.
    OpenUrlAbstract
  22. ↵
    Emery P and Reppert SM (2004) A rhythmic Ror. Neuron 43: 443-446.
    OpenUrlCrossRefPubMed
  23. ↵
    Escriva H, Delaunay F, and Laudet V (2000) Ligand binding and nuclear receptor evolution. Bioessays 22: 717-727.
    OpenUrlCrossRefPubMed
  24. ↵
    Fayard E, Auwerx J, and Schoonjans K (2004) LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol 14: 250-260.
    OpenUrlCrossRefPubMed
  25. ↵
    Fisher CR, Graves KH, Parlow AF, and Simpson ER (1998) Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 95: 6965-6970.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Flaig R, Greschik H, Peluso-Iltis C, and Moras D (2005) Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain. J Biol Chem 280: 19250-19258.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Francis GA, Fayard E, Picard F, and Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65: 261-311.
    OpenUrlCrossRefPubMed
  28. ↵
    Fuhrmann G, Chung AC, Jackson KJ, Hummelke G, Baniahmad A, Sutter J,Sylvester I, Scholer HR, and Cooney AJ (2001) Mouse germline restriction of Oct4 expression by germ cell nuclear factor. Dev Cell 1: 377-387.
    OpenUrlCrossRefPubMed
  29. ↵
    Giguere V (1999) Orphan nuclear receptors: from gene to function. Endocr Rev 20: 689-725.
    OpenUrlCrossRefPubMed
  30. ↵
    Giguere V (2002) To ERR in the estrogen pathway. Trends Endocrinol Metab 13: 220-225.
    OpenUrlCrossRefPubMed
  31. ↵
    Giguere V, Yang N, Segui P, and Evans RM (1988) Identification of a new class of steroid hormone receptors. Nature (Lond) 331: 91-94.
    OpenUrlCrossRefPubMed
  32. ↵
    Giguère V, Tini M, Flock G, Ong E, Evans RM, and Otulakowski G (1994) Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR α, a novel family of orphan hormone nuclear receptors. Genes Dev 8: 538-553.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Gottlicher M, Widmark E, Li Q, and Gustafsson JA (1992) Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89: 4653-4657.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D, and Renaud JP (2002) Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol Cell 9: 303-313.
    OpenUrlCrossRefPubMed
  35. ↵
    Gu P, Goodwin B, Chung AC, Xu X, Wheeler DA, Price RR, Galardi C, Peng L, Latour AM, Koller BH, et al. (2005a) Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of embryonic development. Mol Cell Biol 25: 3492-3505.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Gu P, Lemenuet D, Chung AC, Mancini M, Wheeler DA, and Cooney AJ (2005b) Orphan nuclear receptor GCNF is required for the repression of pluripotency genes during retinoic acid-induced embryonic stem cell differentiation. Mol Cell Biol 25: 8507-8519.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Gu P, Morgan DH, Sattar M, Xu X, Wagner R, Raviscioni M, Lichtarge O, and Cooney AJ (2005c) Evolutionary trace-based peptides identify a novel asymmetric interaction that mediates oligomerization in nuclear receptors. J Biol Chem 280: 31818-31829.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Guillaumond F, Dardente H, Giguere V, and Cermakian N (2005) Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms 20: 391-403.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Harding HP and Lazar MA (1993) The orphan receptor Rev-ErbAα activates transcription via a novel response element. Mol Cell Biol 13: 3113-3121.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Harding HP and Lazar MA (1995) The monomer-binding orphan receptor Rev-Erb represses transcription as a dimer on a novel direct repeat. Mol Cell Biol 15: 4791-4802.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    He YW (2002) Orphan nuclear receptors in T lymphocyte development. J Leukoc Biol 72: 440-446.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans R, and Thaller C (1992) 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68: 397-406.
    OpenUrlCrossRefPubMed
  43. ↵
    Honda S, Harada N, Ito S, Takagi Y, and Maeda S (1998) Disruption of sexual behavior in male aromatase-deficient mice lacking exons 1 and 2 of the cyp19 gene. Biochem Biophys Res Commun 252: 445-449.
    OpenUrlCrossRefPubMed
  44. ↵
    Honda S, Morohashi K, Nomura M, Takeya H, Kitajima M, and Omura T (1993) Ad4BP regulating steroidogenic P-450 gene is a member of steroid hormone receptor superfamily. J Biol Chem 268: 7494-7502.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Horard B, Rayet B, Triqueneaux G, Laudet V, Delaunay F, and Vanacker JM (2004) Expression of the orphan nuclear receptor ERRα is under circadian regulation in estrogen-responsive tissues. J Mol Endocrinol 33: 87-97.
    OpenUrlAbstract
  46. ↵
    Inoue I, Shinoda Y, Ikeda M, Hayashi K, Kanazawa K, Nomura M, Matsunaga T, Xu H, Kawai S, Awata T, et al. (2005) CLOCK/BMAL1 is involved in lipid metabolism via transactivation of the peroxisome proliferator-activated receptor (PPAR) response element. J Atheroscler Thromb 12: 169-174.
    OpenUrlCrossRefPubMed
  47. ↵
    Janowski BA, Willy PJ, Devi TR, Falck JR, and Mangelsdorf DJ (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature (Lond) 383: 728-731.
    OpenUrlCrossRefPubMed
  48. ↵
    Jetten AM (2004) Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr Drug Targets Inflamm Allergy 3: 395-412.
    OpenUrlCrossRefPubMed
  49. ↵
    Jetten AM, Kurebayashi S, and Ueda E (2001) The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 69: 205-247.
    OpenUrlCrossRefPubMed
  50. ↵
    Kallen J, Schlaeppi JM, Bitsch F, Delhon I, and Fournier B (2004) Crystal structure of the human RORα ligand binding domain in complex with cholesterol sulfate at 2.2 A. J Biol Chem 279: 14033-14038.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Kallen JA, Schlaeppi JM, Bitsch F, Geisse S, Geiser M, Delhon I, and Fournier B (2002) X-ray structure of the hRORα LBD at 1.63 A: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORα. Structure (Camb) 10: 1697-1707.
    OpenUrlPubMed
  52. ↵
    Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, and Negishi M (1999) Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 19: 6318-6322.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Kitareewan S, Burka LT, Tomer KB, Parker CE, Deterding LJ, Stevens RD, Forman BM, Mais DE, Heyman RA, McMorris T, et al. (1996) Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Biol Cell 7: 1153-1166.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Kliewer SA, Lehmann JM, and Willson TM (1999) Orphan nuclear receptors: shifting endocrinology into reverse. Science (Wash DC) 284: 757-760.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Kobayashi M, Takezawa S, Hara K, Yu RT, Umesono Y, Agata K, Taniwaki M, Yasuda K, and Umesono K (1999) Identification of a photoreceptor cell-specific nuclear receptor. Proc Natl Acad Sci USA 96: 4814-4819.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, and Smithies O (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc Natl Acad Sci USA 95: 15677-15682.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, MacKay JA, Juzumiene D, Bynum JM, Madauss K, Montana V, et al. (2005) Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell 120: 343-355.
    OpenUrlCrossRefPubMed
  58. ↵
    Laitinen S, Fontaine C, Fruchart JC, and Staels B (2005) The role of the orphan nuclear receptor Rev-Erbα in adipocyte differentiation and function. Biochimie 87: 21-25.
    OpenUrlPubMed
  59. ↵
    Lee YF, Lee HJ, and Chang C (2002) Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. J Steroid Biochem Mol Biol 81: 291-308.
    OpenUrlCrossRefPubMed
  60. ↵
    Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Investig 102: 1016-1023.
    OpenUrlCrossRefPubMed
  61. ↵
    Lemotte PK, Keidel S, and Apfel CM (1996) Phytanic acid is a retinoid X receptor ligand. Eur J Biochem 236: 328-333.
    OpenUrlPubMed
  62. ↵
    Lengqvist J, Mata De Urquiza A, Bergman AC, Willson TM, Sjovall J, Perlmann T, and Griffiths WJ (2004) Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor α ligand-binding domain. Mol Cell Proteomics 3: 692-703.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, Bingham NC, Kliewer SA, and Xu HE (2005) Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell 17: 491-502.
    OpenUrlCrossRefPubMed
  64. ↵
    Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, and Smithies O (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90: 11162-11166.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Luo J, Sladek R, Bader JA, Matthyssen A, Rossant J, and Giguere V (1997) Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-β. Nature (Lond) 388: 778-782.
    OpenUrlCrossRefPubMed
  66. ↵
    Luo J, Sladek R, Carrier J, Bader JA, Richard D, and Giguere V (2003) Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor α. Mol Cell Biol 23: 7947-7956.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, and Shan B (1999) Identification of a nuclear receptor for bile acids. Science (Wash DC) 284: 1362-1365.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Mangelsdorf DJ and Evans RM (1995) The RXR heterodimers and orphan receptors. Cell 83: 841-850.
    OpenUrlCrossRefPubMed
  69. ↵
    Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
    OpenUrlCrossRefPubMed
  70. ↵
    Mata de Urquiza A, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, and Perlmann T (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science (Wash DC) 290: 2140-2144.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    Nemoto Y, Toda K, Ono M, Fujikawa-Adachi K, Saibara T, Onishi S, Enzan H, Okada T, and Shizuta Y (2000) Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Investig 105: 1819-1825.
    OpenUrlCrossRefPubMed
  72. ↵
    Pare JF, Malenfant D, Courtemanche C, Jacob-Wagner M, Roy S, Allard D, and Belanger L (2004) The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element. J Biol Chem 279: 21206-21216.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    Park JI, Tsai SY, and Tsai MJ (2003) Molecular mechanism of chicken ovalbumin upstream promoter-transcription factor (COUP-TF) actions. Keio J Med 52: 174-181.
    OpenUrlCrossRefPubMed
  74. ↵
    Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science (Wash DC) 284: 1365-1368.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    Perlmann T and Jansson L (1995) A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev 9: 769-782.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    Perlmann T and Wallen-Mackenzie A (2004) Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res 318: 45-52.
    OpenUrlCrossRefPubMed
  77. ↵
    Preitner N, Brown S, Ripperger J, Le-Minh N, Damiola F, and Schibler U (2003) Orphan nuclear receptors, molecular clockwork, and the entrainment of peripheral oscillators. Novartis Found Symp 253: 89-99.
    OpenUrlCrossRefPubMed
  78. ↵
    Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, and Schibler U (2002) The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110: 251-260.
    OpenUrlCrossRefPubMed
  79. ↵
    Rastinejad F, Perlmann T, Evans RM, and Sigler PB (1995) Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature (Lond) 375: 203-211.
    OpenUrlCrossRefPubMed
  80. ↵
    Reinking J, Lam MM, Pardee K, Sampson HM, Liu S, Yang P, Williams S, White W, Lajoie G, Edwards A, et al. (2005) The Drosophila nuclear receptor e75 contains heme and is gas responsive. Cell 122: 195-207.
    OpenUrlCrossRefPubMed
  81. ↵
    Renaud JP, Harris JM, Downes M, Burke LJ, and Muscat GE (2000) Structure-function analysis of the Rev-erbA and RVR ligand-binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains. Mol Endocrinol 14: 700-717.
    OpenUrlCrossRefPubMed
  82. ↵
    Robinson-Rechavi M and Laudet V (2003) Bioinformatics of nuclear receptors. Methods Enzymol 364: 95-118.
    OpenUrlPubMed
  83. ↵
    Ruse MD Jr, Privalsky ML, and Sladek FM (2002) Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4α1: modulation by the F domain. Mol Cell Biol 22: 1626-1638.
    OpenUrlAbstract/FREE Full Text
  84. ↵
    Sablin EP, Krylova IN, Fletterick RJ, and Ingraham HA (2003) Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1. Mol Cell 11: 1575-1585.
    OpenUrlCrossRefPubMed
  85. ↵
    Seol W, Choi HS, and Moore DD (1996) An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science (Wash DC) 272: 1336-1339.
    OpenUrlAbstract
  86. ↵
    Shiau AK, Coward P, Schwarz M, and Lehmann JM (2001) Orphan nuclear receptors: from new ligand discovery technologies to novel signaling pathways. Curr Opin Drug Discov Dev 4: 575-590.
    OpenUrlPubMed
  87. ↵
    Sladek R, Bader JA, and Giguere V (1997) The orphan nuclear receptor estrogen-related receptor α is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene. Mol Cell Biol 17: 5400-5409.
    OpenUrlAbstract/FREE Full Text
  88. ↵
    Sladek R and Giguere V (2000) Orphan nuclear receptors: an emerging family of metabolic regulators. Adv Pharmacol 47: 23-87.
    OpenUrlPubMed
  89. ↵
    Stehlin C, Wurtz JM, Steinmetz A, Greiner E, Schule R, Moras D, and Renaud JP (2001) X-ray structure of the orphan nuclear receptor RORβ ligand-binding domain in the active conformation. EMBO (Eur Mol Biol Organ) J 20: 5822-5831.
    OpenUrlAbstract
  90. ↵
    Stehlin-Gaon C, Willmann D, Zeyer D, Sanglier S, Van Dorsselaer A, Renaud JP, Moras D, and Schule R (2003) All-trans retinoic acid is a ligand for the orphan nuclear receptor RORβ. Nat Struct Biol 10: 820-825.
    OpenUrlCrossRefPubMed
  91. ↵
    Tremblay GB, Bergeron D, and Giguere V (2001a) 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. Endocrinology 142: 4572-4575.
    OpenUrlCrossRefPubMed
  92. ↵
    Tremblay GB, Kunath T, Bergeron D, Lapointe L, Champigny C, Bader JA, Rossant J, and Giguere V (2001b) Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERRβ. Genes Dev 15: 833-838.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    Triqueneaux G, Thenot S, Kakizawa T, Antoch MP, Safi R, Takahashi JS, Delaunay F, and Laudet V (2004) The orphan receptor Rev-erbα gene is a target of the circadian clock pacemaker. J Mol Endocrinol 33: 585-608.
    OpenUrlAbstract/FREE Full Text
  94. ↵
    Tzameli I and Moore DD (2001) Role reversal: new insights from new ligands for the xenobiotic receptor CAR. Trends Endocrinol Metab 12: 7-10.
    OpenUrlCrossRefPubMed
  95. ↵
    Tzameli I, Pissios P, Schuetz EG, and Moore DD (2000) The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 20: 2951-2958.
    OpenUrlAbstract/FREE Full Text
  96. ↵
    Volakakis N, Malewicz M, Kadkhodai B, Perlmann T, and Benoit G (2006) Characterization of the Nurr1 ligand-binding domain co-activator interaction surface. J Mol Endocrinol 37: 317-326.
    OpenUrlAbstract/FREE Full Text
  97. ↵
    Wang LH, Tsai SY, Cook RG, Beattie WG, Tsai MJ, and O'Malley BW (1989) COUP transcription factor is a member of the steroid receptor superfamily. Nature (Lond) 340: 163-166.
    OpenUrlCrossRefPubMed
  98. ↵
    Wang W, Zhang C, Marimuthu A, Krupka HI, Tabrizizad M, Shelloe R, Mehra U, Eng K, Nguyen H, Settachatgul C, et al. (2005) The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. Proc Natl Acad Sci USA 102: 7505-7510.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    Wang Z, Benoit G, Liu J, Prasad S, Aarnisalo P, Liu X, Xu H, Walker NP, and Perlmann T (2003) Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (Lond) 423: 555-560.
    OpenUrlCrossRefPubMed
  100. ↵
    Warnecke M, Oster H, Revelli JP, Alvarez-Bolado G, and Eichele G (2005) Abnormal development of the locus coeruleus in Ear2 (Nr2f6)-deficient mice impairs the functionality of the forebrain clock and affects nociception. Genes Dev 19: 614-625.
    OpenUrlAbstract/FREE Full Text
  101. ↵
    Watt AJ, Garrison WD, and Duncan SA (2003) HNF4: a central regulator of hepatocyte differentiation and function. Hepatology 37: 1249-1253.
    OpenUrlCrossRefPubMed
  102. ↵
    Willson TM (2002) RORα: an orphan nuclear receptor on a high-cholesterol diet. Structure (Camb) 10: 1605-1606.
    OpenUrlPubMed
  103. ↵
    Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550.
    OpenUrlCrossRefPubMed
  104. ↵
    Wilson TE, Fahrner TJ, Johnston M, and Milbrandt J (1991) Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science (Wash DC) 252: 1296-1300.
    OpenUrlAbstract/FREE Full Text
  105. ↵
    Wilson TE, Fahrner TJ, and Milbrand J (1993) The orphan receptors NGFI-B and steroidogenic factor 1 establish monomer binding as a third paradigm of nuclear receptor-DNA interaction. Mol Cell Biol 13: 5794-5804.
    OpenUrlAbstract/FREE Full Text
  106. ↵
    Wisely GB, Miller AB, Davis RG, Thornquest AD Jr, Johnson R, Spitzer T, Sefler A, Shearer B, Moore JT, Miller AB, et al. (2002) Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure (Camb) 10: 1225-1234.
    OpenUrlPubMed
  107. ↵
    Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, and Gronemeyer H (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3: 87-94.
    OpenUrlCrossRefPubMed
  108. ↵
    Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP, McCabe ER, et al. (1994) An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature (Lond) 372: 635-641.
    OpenUrlCrossRefPubMed
  109. ↵
    Zechel C (2005) The germ cell nuclear factor (GCNF). Mol Reprod Dev 72: 550-556.
    OpenUrlCrossRefPubMed
  110. ↵
    Zetterstrom RH, Solomin L, Mitsiadis T, Olson L, and Perlmann T (1996) Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol Endocrinol 10: 1656-1666.
    OpenUrlCrossRefPubMed
  111. ↵
    Zhang Y and Dufau ML (2004) Gene silencing by nuclear orphan receptors. Vitam Horm 68: 1-48.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 58 (4)
Pharmacological Reviews
Vol. 58, Issue 4
1 Dec 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
International Union of Pharmacology. LXVI. Orphan Nuclear Receptors
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Issue IUPHAR Compendium of the Pharmacology and Classification of the Nuclear Receptor Superfamily 2006

International Union of Pharmacology. LXVI. Orphan Nuclear Receptors

Gérard Benoit, Austin Cooney, Vincent Giguere, Holly Ingraham, Mitch Lazar, George Muscat, Thomas Perlmann, Jean-Paul Renaud, John Schwabe, Frances Sladek, Ming-Jer Tsai and Vincent Laudet
Pharmacological Reviews December 1, 2006, 58 (4) 798-836; DOI: https://doi.org/10.1124/pr.58.4.10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Issue IUPHAR Compendium of the Pharmacology and Classification of the Nuclear Receptor Superfamily 2006

International Union of Pharmacology. LXVI. Orphan Nuclear Receptors

Gérard Benoit, Austin Cooney, Vincent Giguere, Holly Ingraham, Mitch Lazar, George Muscat, Thomas Perlmann, Jean-Paul Renaud, John Schwabe, Frances Sladek, Ming-Jer Tsai and Vincent Laudet
Pharmacological Reviews December 1, 2006, 58 (4) 798-836; DOI: https://doi.org/10.1124/pr.58.4.10
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • What Are Orphan Receptors?
    • Biological Functions of Orphan Receptors
    • Unorthodox LBD for Unorthodox NRs
    • The Paradox: Toward Pharmacology of Orphan Receptors?
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
  • Foreword
Show more Special Issue IUPHAR Compendium of the Pharmacology and Classification of the Nuclear Receptor Superfamily 2006

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics